Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718156 | 0.92 | CYP2C19 (0.64) | CD274TNKS2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3456158 | 0.88 | DPP7 (0.59) | CD274CYP3A4CYP2D6EPHX2ALDH1A1 | |
| SCHEMBL3458281 | 0.86 | DPP7 (0.57) | CD274CYP3A4CYP2D6EPHX2ALDH1A1 | |
| SCHEMBL3166127 | 0.84 | CYP2D6 (0.65) | TNKS2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL4246716 | 0.83 | DPP7 (0.60) | CD274TNKS2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4423135 | 0.82 | POLB (0.58) | CD274TNKS2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL5754540 | 0.82 | DPP7 (0.62) | CYP3A4CYP2D6EPHX2ALDH1A1HRH3 | |
| Hydrochloric Acid SCHEMBL5754920 | 0.81 | DPP7 (0.60) | CYP3A4CYP2D6EPHX2ALDH1A1HRH3 | |
| SCHEMBL4718128 | 0.80 | CACNA1B (0.52) | CYP3A4CYP2D6CYP2C19EPHX2ALDH1A1 | |
| SCHEMBL4717385 | 0.79 | CACNA1B (0.53) | CYP3A4CYP2D6CYP2C19ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | CD274 4190/4885TNKS2 836/4885CYP3A4 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.